Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001376627 | SCV001218684 | pathogenic | Primary pulmonary hypertension | 2022-02-28 | criteria provided, single submitter | clinical testing | This missense change has been observed in individuals with pulmonary arterial hypertension (PMID: 15146475, 21737554, 21801371; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 420 of the BMPR2 protein (p.Cys420Tyr). ClinVar contains an entry for this variant (Variation ID: 425907). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Cys420 amino acid residue in BMPR2. Other variant(s) that disrupt this residue have been observed in individuals with BMPR2-related conditions (PMID: 21801371, 27453251), which suggests that this may be a clinically significant amino acid residue. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BMPR2 protein function. |
| Rare Disease Genomics Group, |
RCV000488809 | SCV000576200 | pathogenic | Pulmonary hypertension, primary, 1 | no assertion criteria provided | literature only |